NCT01933594: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01933594 |
|---|---|
| Title | A Phase I/II Study of Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 5, 2014 |
| Completion date | April 16, 2018 |
| Required reporting date | April 16, 2019, midnight |
| Actual reporting date | April 3, 2019 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |